BCI Companies

BCI Companies Index

Overview

BCI Companies Index

Overview

Brain-computer interface (BCI) technology represents one of the most transformative frontiers in neuroscience and neurotechnology. BCI systems enable direct communication between the brain and external devices, with applications spanning medical therapeutics, cognitive augmentation, and neural prosthetics. For neurodegenerative disease research, BCI technology offers revolutionary possibilities for restoring function in patients with movement disorders, communication deficits, and sensory impairments["@braincomputer"].

This page provides comprehensive coverage of companies developing BCI technologies, including implantable neural interfaces, non-invasive EEG systems, and emerging therapeutic applications for neurological conditions.

Market Landscape

The BCI market has experienced unprecedented growth since 2020, driven by:

• Advancements in miniaturization: Semiconductor and microfabrication advances enabling smaller, more sophisticated neural implants
• Machine learning improvements: Better signal processing and neural decoding algorithms
• Regulatory progress: FDA breakthrough device designations and first-in-human trials
• Investment surge: Over $1 billion invested in BCI startups since 2021

Invasive BCI Companies

Neuralink

Headquarters: Fremont, California, USA Status: Human clinical trials (PRIME Study)

Neuralink develops the N1 implant, a fully implantable, wireless brain-computer interface with 1,024+ electrodes. The company received FDA breakthrough device designation in 2020 and began human trials in 2023. Neuralink's technology targets movement restoration, vision prosthesis, and communication applications[@neuralink][@neuralinka].

See Neuralink for detailed coverage.

Synchron

Headquarters: New York, New York, USA Ticker: Private Status: Clinical trials (COMMANDER Study)

Synchron developed the Stentrode, a minimally invasive neural interface that routes through the jugular vein to the motor [cortex](/brain-regions/cortex). Unlike traditional brain implants, Stentrode does not require open-brain surgery. The device received FDA breakthrough device designation in 2020 and is currently in human trials for patients with paralysis[@synchron].

See Synchron for detailed coverage.

Technology:
| Feature | Specification |
|---------|---------------|
| Implantation | Endovascular (jugular vein) |
| Electrodes | 16-channel stent-array |
| Data transmission | Wireless |
| Target | Motor cortex |

Blackrock Neurotech

Headquarters: Salt Lake City, Utah, USA Status: Clinical (Longest-running BCI company)

Blackrock Neurotech has been developing neural interfaces since 2008 and holds the longest record of human BCI implantations. The Utah Array has been used in numerous research studies and early clinical applications[@blackrock].

Products:
| Product | Description | Status |
|---------|-------------|--------|
| Utah Array | Rigid microelectrode array | Clinical |
| NeuroPort | Integrated recording system | Commercial |
| Blackrock SIMS | Smart implant system | Development |

Paradromics

Headquarters: Los Angeles, California, USA Status: Preclinical

Paradromics is developing the Connexus Direct Data Interface, a high-bandwidth neural implant designed for communication restoration. The company focuses on patients with locked-in syndrome and severe paralysis[@paradromics].

Technical Specifications:

• Channels: 1,000+ simultaneous recordings
• Data rate: High-bandwidth neural streaming
• Target: Speech restoration

Precision Neuroscience

Headquarters: New York, New York, USA Status: Clinical

Precision Neuroscience developed the Layer 7 Cortical Interface, a thin-film electrode array that sits on the brain surface rather than penetrating tissue. This approach aims to reduce tissue damage while maintaining high signal quality[@precision].

Non-Invasive BCI Companies

Additional Invasive BCI Companies

• Blackrock Neurotech — Pioneering Utah Array technology with longest human implantation record
• Paradromics — Developing high-bandwidth neural interfaces for medical applications

Additional Non-Invasive BCI Companies

• BrainCo — Focus neurotechnology on education and healthcare applications
• Kernel — Building non-invasive neural interfaces for cognitive enhancement
• Cerebras — AI computing with neural network applications
• Neurable — Consumer-grade brain-computer interfaces
• Bitbrain — EEG-based BCI solutions for research and healthcare

EMOTIV

Headquarters: San Francisco, California, USA Status: Commercial

EMOTIV develops consumer and research-grade EEG headsets for brain-computer interface applications. Their technology enables thought-controlled interactions with computers and applications^8].

See EMOTIV for detailed coverage.

g.tec

Headquarters: Graz, Austria Status: Commercial

g.tec is a leading provider of high-performance EEG systems for research, clinical, and BCI applications. The company offers both hardware and software solutions for neural signal acquisition and processing^9].

See g.tec for detailed coverage.

Muse

Headquarters: Toronto, Ontario, Canada Status: Consumer commercial

InteraXON (Muse) develops consumer EEG headbands for meditation and brain training applications. While primarily focused on wellness, their technology represents accessible BCI for consumers^10].

NextMind

Headquarters: Paris, France Status: Commercial (Acquired by Snap Inc.)

NextMind developed a non-invasive EEG-based brain-sensing device for visual perception decoding. The company was acquired by Snap Inc. in 2021^11].

BCI for Neurodegenerative Disease

Applications in Alzheimer's Disease and Parkinson's

BCI technology offers several therapeutic applications for neurodegenerative :

| Application | Technology | Target Condition |
|-------------|------------|------------------|
| Deep brain stimulation | Invasive electrodes | PD, AD |
| Motor restoration | Neural prosthetics | PD, ALS |
| Cognitive monitoring | EEG | AD progression |
| Communication | BCI | ALS, locked-in |
| Memory enhancement | Neural interfaces | AD |

Companies Targeting Neurodegeneration

Several BCI companies specifically focus on neurodegenerative disease applications:

• Neuralink: Clinical trials include ALS and spinal cord injury patients
• Synchron: Targeting motor impairment in various neurological conditions
• Blackrock Neurotech: Research applications in PD and AD
• g.tec: EEG monitoring for AD progression tracking

Clinical Trial Status

Active Clinical Trials

| Company | Device | Indication | Stage |
|---------|--------|------------|-------|
| Neuralink | N1 | Paralysis | Phase 1 |
| Synchron | Stentrode | Paralysis | Phase 1 |
| Blackrock | Utah Array | Research | Clinical |
| Precision Neuroscience | Layer 7 | Epilepsy | Phase 1 |

FDA Breakthrough Device Designations

• Neuralink N1 (2020)
• Synchron Stentrode (2020)
• Paradromics Connexus (2023)
• Precision Neuroscience Layer 7 (2023)

Funding and Investment

Notable Funding Rounds

| Company | Funding | Year | Investors |
|---------|---------|------|-----------|
| Neuralink | $680M | 2024 | Founders Fund, GV |
| Synchron | $100M | 2022 | Khosla, Andreessen |
| Paradromics | $72M | 2023 | ARCH, Prime |
| Precision Neuroscience | $93M | 2023 | Andreessen, ...

Market Projections

The BCI market is projected to reach $7-12 billion by 2030, driven by:

• Medical applications (paralysis, neurological disorders)
• Consumer brain training and wellness
• Gaming and VR integration
• Cognitive enhancement research

Pipeline

Technology Comparison

| Company | Modality | Invasiveness | Channels | Status |
|---------|----------|---------------|----------|--------|
| Neuralink | ECoG/Intracortical | Fully invasive | 1,024+ | Human trials |
| Synchron | Endovascular | Minimally invasive | 16 | Human trials |
| Blackrock | Intracortical | Invasive | 100+ | Clinical |
| Paradromics | Intracortical | Invasive | 1,000+ | Preclinical |
| Precision Neuroscience | ECoG | Surface | 1,024+ | Human trials |
| EMOTIV | EEG | Non-invasive | 14-32 | Commercial |
| g.tec | EEG | Non-invasive | 64-256 | Commercial |

Regulatory Pathways

BCI devices navigate FDA's Class III medical device pathway, typically requiring:

Future Directions

Near-term (2025-2027)

• Expansion of human clinical trials
• FDA approvals for first BCI devices
• Improved signal resolution and battery life
• Commercialization of communication prosthetics

Long-term (2028+)

• Fully implantable, rechargeable systems
• Bidirectional neural interfaces (reading and writing)
• Integration with AI for enhanced decoding
• Treatment of additional neurological conditions

Cross-References

• Neuralink
• Synchron
• EMOTIV
• g.tec
• [Parkinson's Disease](/diseases/parkinsons-disease) Treatment
• Deep Brain Stimulation
• [Alzheimer's Disease](/diseases/alzheimers-disease) Treatment
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/) KEGG Pathways

References